Gammacan to Explore the Efficacy of IVIg sourced from Specific Population for the Treatment of Malignant Melanoma Patients
30 January 2006 - 11:30PM
Business Wire
Company is Entering Initial Process to Test the Efficacy of a
Unique IVIg as a New and Advanced Malignant Melanoma Treatment
Option Gammacan International (OTC BB:GCAN), a developer of
immunotherapies for cancer and other diseases, today announced that
it is considering an additional clinical trial to demonstrate
clinical efficacy of hyperimmune intravenous immunoglobulin (IVIg),
sourced from a specific population, for treating Melanoma, a common
and serious skin cancer. The Company is presently in a Phase II
clinical trial utilizing its GCAN - 101 for the treatment of
metastatic melanoma, prostate and colon cancers. Although melanoma
accounts for only 4% of all skin cancers, it accounts for more than
70% of all skin cancer deaths and the patient population is
steadily increasing. The Melanoma Research Foundation noted, "No
significant advances in medical therapies (or survival) for
patients with advanced melanoma have occurred in the past 30
years". "We believe that the existing research results regarding
the use of IVIG for treatment of Melanoma provide sufficient
incentive to advance to a clinical stage the efficacy of IVIg
sourced from a specific population for the treatment of Malignant
Melanoma," stated Vered Caplan, CEO. "Expanding our pipeline of
IVIG-based therapies and targeting specific cancers where little
therapeutic benefit has been seen is key to the Company's growth
and to patients suffering from such devastating diseases," Caplan
concluded. About Gammacan: Gammacan is focusing on the
commercialization of a revolutionary anti-cancer immunotherapy that
the Company believes will be proven to be effective in reducing the
metastatic spread of a wide range of cancers. Gammacan's proposed
treatment is based on IVIG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. It works by strengthening the
patient's immune system. Many experts currently view immunotherapy
as a future alternative to today's standard chemotherapy.
Approximately twenty companies produce IVIG, and annual worldwide
sales are currently in excess of 50 metric tones with an estimated
value in excess of 1.5 billion USD. IVIG is commonly used to treat
certain autoimmune diseases and blood disorders and to replace the
antibodies in people who are unable to produce them. For more
information about Gammacan visit www.gammacan.com or call the
company's headquarters in Givat Shmuel, Israel at 972 3 5774475.
Safe Harbor Statement: Statements in this document that are not
purely historical are forward-looking statements. Forward-looking
statements in this release include statements regarding: the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with
IVIG into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
inability to hire appropriate staff to develop the technology,
unforeseen technical difficulties in developing the technology,
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early stage
medical research and development companies filed with the SEC on
Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024